Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease

Roger A Barker, TRANSEURO consortium, Krista Farrell, Natalie Valle Guzman, Xiaoling He, Stanley E Lazic, Sarah Moore, Robert Morris, Pamela Tyers, Ruwani Wijeyekoon, Danielle Daft, Sam Hewitt, Viswas Dayal, Thomas Foltynie, Zinovia Kefalopoulou, Philipp Mahlknecht, Nick P Lao-Kaim, Paola Piccini, Hjalmar Bjartmarz, Anders Björklund, Olle Lindvall, Jenny Nelander-Wahlestedt, Malin Parmar, Gesine Paul, Hakan Widner, Alistair Church, Stephen Dunnett, Kathryn Peall, Anne Rosser, Jean Marc Gurruchaga, Stéphane Palfi, Tobias Piroth, Christian Winkler, Roger A Barker, TRANSEURO consortium, Krista Farrell, Natalie Valle Guzman, Xiaoling He, Stanley E Lazic, Sarah Moore, Robert Morris, Pamela Tyers, Ruwani Wijeyekoon, Danielle Daft, Sam Hewitt, Viswas Dayal, Thomas Foltynie, Zinovia Kefalopoulou, Philipp Mahlknecht, Nick P Lao-Kaim, Paola Piccini, Hjalmar Bjartmarz, Anders Björklund, Olle Lindvall, Jenny Nelander-Wahlestedt, Malin Parmar, Gesine Paul, Hakan Widner, Alistair Church, Stephen Dunnett, Kathryn Peall, Anne Rosser, Jean Marc Gurruchaga, Stéphane Palfi, Tobias Piroth, Christian Winkler

Abstract

Clinical studies of Parkinson's disease (PD) using a dopamine cell replacment strategy have been tried for more than 30 years. The outcomes following transplantation of human fetal ventral mesencephalic tissue (hfVM) have been variable, with some patients coming off their anti-PD treatment for many years and others not responding and/or developing significant side effects, including graft-induced dyskinesia. This led to a re-appraisal of the best way to do such trials, which resulted in a new European-Union-funded allograft trial with fetal dopamine cells across several centers in Europe. This new trial, TRANSEURO ( NCT01898390 ), is an open-label study in which some individuals in a large observational cohort of patients with mild PD who were undergoing identical assessments were randomly selected to receive transplants of hfVM. The TRANSEURO trial is currently ongoing as researchers have completed both recruitment into a large multicenter observational study of younger onset early-stage PD and transplantation of hfVM in 11 patients. While completion of TRANSEURO is not expected until 2021, we feel that sharing the rationale for the design of TRANSEURO, along with the lessons we have learned along the way, can help inform researchers and facilitate planning of transplants of dopamine-producing cells derived from human pluripotent stem cells for future clinical trials.

References

    1. Goedert, M., Spillantini, M. G., Del Tredici, K. & Braak, H. 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13–24 (2013).
    1. Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 18, 509 (2017).
    1. Barker, R. A., Drouin-Ouellet, J. & Parmar, M. Cell-based therapies for Parkinson disease — past insights and future potential. Nat. Rev. Neurol. 11, 492–503 (2015).
    1. Palfi, S. et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383, 1138–1146 (2014).
    1. Freed, C. R. et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N. Engl. J. Med. 344, 710–719 (2001).
    1. Olanow, C. W. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann. Neurol. 54, 403–414 (2003).
    1. Barker, R. A., Barrett, J., Mason, S. L. & Bjorklund, A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson’s disease. Lancet Neurol. 12, 84–91 (2013).
    1. Kirkeby, A., Parmar, M. & Barker, R. A. Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD). Prog. Brain. Res. 230, 165–190 (2017).
    1. Liu, G. et al. Prediction of cognition in Parkinson’s disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol. 16, 620–629 (2017).
    1. Politis, M. et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson’s patients with neural transplants. Sci. Transl. Med. 2, 38ra46 (2010).
    1. Piccini, P. et al. Factors affecting the clinical outcome after neural transplantation in Parkinson’s disease. Brain 128, 2977–2986 (2005).
    1. Piccini, P. et al. Delayed recovery of movement-related cortical function in Parkinson’s disease after striatal dopaminergic grafts. Ann. Neurol. 48, 689–695 (2000).
    1. Piroth, T. et al. Transplantation of human fetal tissue for neurodegenerative diseases: validation of a new protocol for microbiological analysis and bacterial decontamination. Cell Transplant. 23, 995–1007 (2014).
    1. Rath, A. et al. Survival and functional restoration of human fetal ventral mesencephalon following transplantation in a rat model of Parkinson’s disease. Cell Transplant. 22, 1281–1293 (2013).
    1. Kelly, C. M. et al. Medical terminations of pregnancy: a viable source of tissue for cell replacement therapy for neurodegenerative disorders. Cell Transplant. 20, 503–513 (2011).
    1. Kordower, J. H. et al. Functional fetal nigral grafts in a patient with Parkinson’s disease: chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 370, 203–230 (1996).
    1. Li, W. et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc. Natl Acad. Sci. USA 113, 6544–6549 (2016).
    1. Brundin, P. et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s disease. Brain 123, 1380–1390 (2000).
    1. Kefalopoulou, Z. et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 71, 83–87 (2014).
    1. Fahn, S. et al. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med. 351, 2498–2508 (2004).
    1. Carpenter, B. et al.Stan: a probabilistic programming language. J. Stat. Softw. 76, (2017).
    1. Bürkner, P. brms: An R Package for Bayesian Multilevel Models Using Stan. J. Stat. Softw. 80, (2017).
    1. Li, W. et al. (11) C-PE2I and (18) F-Dopa PET for assessing progression rate in Parkinson’s: A longitudinal study. Mov. Disord. 33, 117–127 (2018).
    1. Lindvall, O. et al. Transplantation of fetal dopamine neurons in Parkinson’s disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann. Neurol. 31, 155–165 (1992).
    1. Lindvall, O. et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46, 615–631 (1989).
    1. Laguna Goya, R., Busch, R., Mathur, R., Coles, A. J. & Barker, R. A. Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation. Neurobiol. Dis. 41, 407–414 (2011).
    1. Liu, X., Li, W., Fu, X. & Xu, Y. The immunogenicity and immune tolerance of pluripotent stem cell derivatives. Front. Immunol. 8, 645 (2017).
    1. Scheiner, Z. S., Talib, S. & Feigal, E. G. The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies. J. Biol. Chem. 289, 4571–4577 (2014).
    1. Galpern, W. R. et al. Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol. 11, 643–650 (2012).

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel